Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FCN-159 in histiocytic tumors (LCH/ECD and others)
CTR20221069Phase 2Completed
- Sponsor
- Fosun Pharma
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of luvometinib in histiocytic disease, Langerhans cell histiocytosis (LCH), Erdheim-Chester disease (ECD), sponsored by Fosun Pharma. Started May 2022; status: completed.
02
Drugs
luvometinib
03
Conditions
histiocytic diseaseLangerhans cell histiocytosis (LCH)Erdheim-Chester disease (ECD)
Beyond the preview
Go deeper on CTR20221069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221069.